Previously, we watched Tim Berners-Lee knit the world together with the Web, giving us pages to browse and links to click. But a web of information is useless if the physical network carrying it ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

The Recursive Division Tree (RDT) algorithm is a mathematical process for measuring the logarithmic height of positive integers. For any integer ( n \ge 2 ), it recursively divides by logarithm-based ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

This paper first discusses the storage structure of trees, selects a convenient storage method for solving the nullity of trees, and then applies the relationship between the maximum matching number ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

MicroAlgo Inc. announced its research on the Quantum Information Recursive Optimization (QIRO) algorithm, which aims to address complex combinatorial optimization problems using quantum computing.

AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly ...

1 Computer Science Department, Babcock University, Ilishan-Remo, Ogun State, Nigeria. 2 Computer Science Department, Adeleke University, Ede, Osun State, Nigeria. 3 Department of Applied Mathematics, ...

Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...